Related Experiment Video
Updated: Jun 19, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer
Kiranmai Gumireddy1, Anping Li, Phyllis A Gimotty
1The Wistar Institute, 3601 Spruce Street, PA 19104, USA.
Abstract:
Metastasis is a complex multistep process, which requires the concerted action of many genes and is the primary cause of cancer death. Both pathways that regulate metastasis enhancement and those that regulate its suppression contribute to the tumour dissemination process. To identify new metastasis suppressors, we set up a forward genetic screen in a mouse model. We transduced a genome-wide RNA interference (RNAi) library into the non-metastatic 168FARN breast cancer cell line and orthotopically transplanted the cells into mouse mammary fat pads. We then selected cells that could metastasize to the lung and identified an RNAi for the KLF17 gene. Conversely, we demonstrate that ectopic expression of KLF17 in a highly metastatic 4T1 breast cancer cell line inhibits the ability of cells to metastasize from the mammary fat pad to the lung. We also show that suppression of KLF17 expression promotes breast cancer cell invasion and epithelial-mesenchymal transition (EMT), and that KLF17 protein functions by directly binding to the promoter region of Id1 (which encodes a key metastasis regulator in breast cancer) to inhibit its transcription. Finally, we demonstrate that KLF17 expression is significantly downregulated in primary human breast cancer samples and that the combined expression pattern of KLF17 and Id1 can serve as a potential biomarker for lymph node metastasis in breast cancer.
Insights
Researchers identified KLF17 as a novel breast cancer metastasis suppressor. Lower KLF17 levels promote cancer spread and invasion, suggesting its potential as a biomarker for metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastasis, a key factor in cancer mortality, involves complex genetic regulation.
- Identifying metastasis suppressors is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To discover novel genes that suppress breast cancer metastasis using a forward genetic screen.
- To elucidate the mechanism by which KLF17 regulates metastasis and its potential as a biomarker.
Main Methods:
- Genome-wide RNA interference (RNAi) screen in a mouse breast cancer model.
- Orthotopic transplantation of engineered cells and selection for metastatic variants.
- Analysis of KLF17's effect on cell invasion, epithelial-mesenchymal transition (EMT), and Id1 gene expression.
- Validation in human breast cancer samples.
Main Results:
- KLF17 was identified as a novel metastasis suppressor gene.
- KLF17 expression inhibits breast cancer cell metastasis, invasion, and EMT.
- KLF17 directly suppresses the transcription of Id1, a key metastasis regulator.
- KLF17 is downregulated in human breast cancers, and KLF17/Id1 expression predicts lymph node metastasis.
Conclusions:
- KLF17 acts as a critical suppressor of breast cancer metastasis.
- KLF17's regulatory role in Id1 transcription and its downregulation in human tumors highlight its significance.
- KLF17 and Id1 expression patterns may serve as valuable biomarkers for predicting breast cancer metastasis.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle
Negative Regulator Molecules
lncRNA - Long Non-coding RNAs
